COLL Collegium Pharmaceutical Inc.

20.95
-0.22  -1%
Previous Close 21.17
Open 21.65
Price To Book 8.35
Market Cap 702,392,263
Shares 33,527,077
Volume 329,057
Short Ratio
Av. Daily Volume 471,086
Stock charts supplied by TradingView

NewsSee all news

  1. Collegium Provides 2020 Financial Guidance

    – Xtampza® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 – STOUGHTON, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical

  2. Collegium to Participate in Upcoming Investor Conferences

    STOUGHTON, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that

  3. Collegium to Participate in Upcoming Investor Conference

    STOUGHTON, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that

  4. Collegium Reports Third Quarter 2019 Financial Results

    – New Exclusive Formulary Wins Announced for Xtampza® ER Effective January 1, 2020 Covering More than 35 Million Lives – – Xtampza® ER Net Product Revenues Were $26.5 Million in the Third Quarter of 2019, a 56% Increase

  5. Collegium to Participate in Upcoming Investor Conference

    STOUGHTON, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced November 7, 2017.
Xtampza ER (oxycodone)
Severe pain
Approved April 26 2016
Xtampza ER (oxycodone)
Severe pain

Latest News

  1. Collegium Provides 2020 Financial Guidance

    – Xtampza® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 – STOUGHTON, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical

  2. Collegium to Participate in Upcoming Investor Conferences

    STOUGHTON, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that

  3. Collegium to Participate in Upcoming Investor Conference

    STOUGHTON, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that

  4. Collegium Reports Third Quarter 2019 Financial Results

    – New Exclusive Formulary Wins Announced for Xtampza® ER Effective January 1, 2020 Covering More than 35 Million Lives – – Xtampza® ER Net Product Revenues Were $26.5 Million in the Third Quarter of 2019, a 56% Increase

  5. Collegium to Participate in Upcoming Investor Conference

    STOUGHTON, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that

  6. Collegium to Participate in Upcoming Investor Conferences

    STOUGHTON, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that

  7. Collegium Announces Scientific Presentations at PAINWeek 2019 National Conference

    STOUGHTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that